Compared with patients without hepatotoxicity, patients with hepatotoxicity had a higher CD4 count at the start of TMP/SMX (median, 48 vs 29 cells/μL, P = 0.083), were less likely to have concomitant use of cART (55.3% vs 73.1%, P = 0.031) and fluconazole (51.1% vs 61.9%, P = 0.191), and were more likely to develop respiratory failure (29.8% vs 18.7%, P = 0.110) in univariate analysis. The gene discussed is CD4; the disease is respiratory failure.